Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia

Eleni Tholouli; Effie Liakopoulou; Hayley M. Greenfield; Bronwen E. Shaw; Sudhir Tauro; Jennifer L. Byrne; Mike Dennis; John Burthem; Guy S. Lucas; Charles Craddock; Nigel H. Russell; John A. Liu Yin

doi:10.1111/j.1365-2141.2008.07184.x

Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia

Eleni Tholouli
, Effie Liakopoulou
, Hayley M. Greenfield
, Bronwen E. Shaw
, Sudhir Tauro
, Jennifer L. Byrne
, Mike Dennis
, John Burthem
, Guy S. Lucas
, Charles Craddock
, Nigel H. Russell
, John A. Liu Yin

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	318-320
Number of pages	3
Journal	British Journal of Haematology
Volume	142
Issue number	2
DOIs	https://doi.org/10.1111/j.1365-2141.2008.07184.x
Publication status	Published - Jul 2008

Keywords

alemtuzumab
acute myeloid leukaemia
poor risk myelodysplasia
reduced intensity conditioning
stem cell transplant
VERSUS-HOST-DISEASE
BONE-MARROW
MALIGNANCIES
REGIMEN

Access to Document

10.1111/j.1365-2141.2008.07184.x

Cite this

Tholouli, E., Liakopoulou, E., Greenfield, H. M., Shaw, B. E., Tauro, S., Byrne, J. L., Dennis, M., Burthem, J., Lucas, G. S., Craddock, C., Russell, N. H., & Yin, J. A. L. (2008). Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. British Journal of Haematology, 142(2), 318-320. https://doi.org/10.1111/j.1365-2141.2008.07184.x

@article{54950ee5df46416bb35ba88ba6e2622a,

title = "Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia",

keywords = "alemtuzumab, acute myeloid leukaemia, poor risk myelodysplasia, reduced intensity conditioning, stem cell transplant, VERSUS-HOST-DISEASE, BONE-MARROW, MALIGNANCIES, REGIMEN",

author = "Eleni Tholouli and Effie Liakopoulou and Greenfield, \{Hayley M.\} and Shaw, \{Bronwen E.\} and Sudhir Tauro and Byrne, \{Jennifer L.\} and Mike Dennis and John Burthem and Lucas, \{Guy S.\} and Charles Craddock and Russell, \{Nigel H.\} and Yin, \{John A. Liu\}",

year = "2008",

month = jul,

doi = "10.1111/j.1365-2141.2008.07184.x",

language = "English",

volume = "142",

pages = "318--320",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "2",

}

Tholouli, E, Liakopoulou, E, Greenfield, HM, Shaw, BE, Tauro, S, Byrne, JL, Dennis, M, Burthem, J, Lucas, GS, Craddock, C, Russell, NH & Yin, JAL 2008, 'Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia', British Journal of Haematology, vol. 142, no. 2, pp. 318-320. https://doi.org/10.1111/j.1365-2141.2008.07184.x

Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. / Tholouli, Eleni; Liakopoulou, Effie; Greenfield, Hayley M. et al.
In: British Journal of Haematology, Vol. 142, No. 2, 07.2008, p. 318-320.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia

AU - Tholouli, Eleni

AU - Liakopoulou, Effie

AU - Greenfield, Hayley M.

AU - Shaw, Bronwen E.

AU - Tauro, Sudhir

AU - Byrne, Jennifer L.

AU - Dennis, Mike

AU - Burthem, John

AU - Lucas, Guy S.

AU - Craddock, Charles

AU - Russell, Nigel H.

AU - Yin, John A. Liu

PY - 2008/7

Y1 - 2008/7

KW - alemtuzumab

KW - acute myeloid leukaemia

KW - poor risk myelodysplasia

KW - reduced intensity conditioning

KW - stem cell transplant

KW - VERSUS-HOST-DISEASE

KW - BONE-MARROW

KW - MALIGNANCIES

KW - REGIMEN

U2 - 10.1111/j.1365-2141.2008.07184.x

DO - 10.1111/j.1365-2141.2008.07184.x

M3 - Letter

C2 - 18492100

SN - 0007-1048

VL - 142

SP - 318

EP - 320

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -